Identification of de novo mutations for ARID1B haploinsufficiency associated with Coffin–Sirs syndrome 1 in three Chinese families via array-CGH and whole exome sequencing

Guanting Lu1*,†, Qiongling Peng2†, Lianying Wu1, Jian Zhang1 and Liya Ma2*

Abstract

Background: Coffin–Sirs syndrome (CSS) is a multiple malformation syndrome characterized by intellectual disability associated with coarse facial features, hirsutism, sparse scalp hair, and hypoplastic or absent fifth fingernails or toenails. CSS represents a small group of intellectual disability, and could be caused by at least twelve genes. The genetic background is quite heterogenous, making it difficult for clinicians and genetic consultors to pinpoint the exact disease types.

Methods: Array-Comparative Genomic Hybridization (array-CGH) and whole exome sequencing (WES) were applied for three trios affected with intellectual disability and clinical features similar with those of Coffin–Sirs syndrome. Sanger sequencing was used to verify the detected single-nucleotide variants (SNVs).

Results: All of the three cases were female with normal karyotypes of 46, XX, born of healthy, non-consanguineous parents. A 6q25 microdeletion (arr[hg19]6q25.3(155,966,487–158,803,979) × 1) (2.84 Mb) (case 1) and two loss-of-function (LoF) mutations of ARID1B [c.2332+1G > A in case 2 and c.4741C > T (p.Q1581X) in case 3] were identified. All of the three pathogenic abnormalities were de novo, not inherited from their parents. After comparison of publicly available microdeletions containing ARID1B, four types of microdeletions leading to insufficient production of ARID1B were identified, namely deletions covering the whole region of ARID1B, deletions covering the promoter region, deletions covering the termination region or deletions covering enhancer regions.

Conclusion: Here we identified de novo ARID1B mutations in three Chinese trios. Four types of microdeletions covering ARID1B were identified. This study broadens current knowledge of ARID1B mutations for clinicians and genetic consultors.
Background

Coffin–Siris syndrome (CSS, OMIM#135900) is a rare congenital anomaly syndrome characterized by intellectual disability, growth deficiency, microcephaly, coarse facial features and hypoplastic nail of the fifth finger and/or toe [1]. Most of the cases were sporadic and showed an autosomal dominant mode of inheritance. The global prevalence of this disease was estimated at approximately 1:10,000–1:100,000 [2].

According to the available reports, the genetics of CSS is quite heterogeneous. Currently, there are 12 types of CSSs caused by pathogenic mutations in different genes: CSS1 (OMIM#135900) by ARID1B (OMIM#614556) [2], CSS2 (OMIM#614607) by ARID1A (OMIM#603024) [3], CSS3 (OMIM#614608) by SMARCB1 (OMIM#601607) [4], CSS4 (OMIM#614609) by SMARCA4 (OMIM#603254) [4], CSS5 (OMIM#616938) by SMARCE1 (OMIM#603111) [4, 5], CSS6 (OMIM#617808) by ARID2 (OMIM#609539) [6], CSS7 (OMIM#618027) by DPF2 (OMIM#601671) [7], CSS8 (OMIM#618362) by SMARCC2 (OMIM#601734) [8], CSS9 (OMIM#615866) by SOX11 (OMIM#600898) [9], CSS10 (OMIM#618506) by SOX4 (OMIM#184430) [10], CSS11 (OMIM#618779) by SMARCD1 (OMIM#601735) [11], and CSS12 (OMIM#619325) by BICRA (OMIM#605690) [12]. It is worth noting the mutations in another gene, SMARCA2 (OMIM#600014) could lead to Nicolaides–Baraitser syndrome (NCBRS; OMIM#601358), which possessed similar phenotypes with Coffin–Siris syndrome [13–15]. Therefore, it is a great challenge for clinicians to identify the disease types and genetic inheritable patterns.

The combination of array-CGH and WES might be an efficient methodology to pinpoint the causal mutations.

Methods

Sample collection

This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. This study was approved by the Ethical Committee of the Shenzhen Bao’an Women’s and Children’s Hospital. Written informed consent was obtained from each individual.

Peripheral venous blood was collected from the three patients and their parents. Genomic DNA was extracted using the TIANamp Blood DNA Kit (DP348, Tiangen Biotech, Beijing, China) according to the manufacturer’s instructions.

Array-comparative genomic hybridization (Array-CGH)

Array-CGH was performed using the Fetal DNA Chip (Version 1.2) designed by The Chinese University of Hong Kong (CUHK) [20, 21]. The chip contains a total of 60,000 probes for more than 100 diseases caused by known microduplication/microdeletions. It doesn’t include small-size chromosomal abnormalities, copy number polymorphism, chimerism and chromosomal rearrangement [22]. The experimental procedures were performed according to the standard Agilent protocol (Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis, version 3.5). Hybridized slides were scanned with SureScan High-Resolution Microarray Scanner (G2505B, Agilent Technologies, Santa Clara, CA, USA), and the image data were extracted and converted to text files using Agilent Feature Extraction software (Version 10.5.1.1). The data were graphed and analyzed using Agilent CGH Analytics software.

Only gains or losses that encompassed by at least three consecutive oligomers on the array were considered. Then, the clinical relevance of observed chromosomal aberrations was estimated according to data found in the scientific literature and databases for each of the regions and genes involved, using the DECIPHER database for known microdeletion and microduplication syndromes and the Online Mendelian Inheritance in Man (OMIM) for known disease-causing genes, gene functions, and inheritance patterns. DNA copy alterations were considered possibly pathogenic when they involved regions known to be associated with microdeletion or microduplication syndromes.
Table 1  Clinical information of the three cases

|                              | Case 1 (Family 1) | Case 2 (Family 2) | Case 3 (Family 3) |
|------------------------------|-------------------|-------------------|-------------------|
| **Genetic detection**        |                   |                   |                   |
| ARID1B mutations             | −                 | c.2332 + 1G > A   | c.4741C > T       |
| −                            |                   | (splicing)        | (p.Q1581X)        |
| arrayCGH                     | 6q25.3 deletion   | −                 | −                 |
| Cytogenetic band deleted     | 46,XX             | 46,XX             | 46,XX             |
| **General information**      |                   |                   |                   |
| Age at report                | 3y5m              | 2y11m             | 3y                |
| Sex                          | Female            | Female            | Female            |
| Birth weight (g)             | 2950              | 2650              | 3200              |
| Birth height (cm)            | NA                | 48                | 50                |
| Head circumstances (cm)      | NA                | 32                | 34                |
| **Facial features**          |                   |                   |                   |
| Thick hair                   | +                 | +                 | +                 |
| Thick eyebrows               | +                 | +                 | +                 |
| Thick eyelashes              | +                 | +                 | +                 |
| Orbital hypertelorism        | −                 | +                 | −                 |
| Down-slanting palpebral fissure | −             | +                 | +                 |
| Up-slanting palpebral fissure | −               | −                 | −                 |
| Nasal root abnormality       | −                 | +                 | −                 |
| Low set ears                 | −                 | −                 | +                 |
| Abnormal ears                | −                 | −                 | −                 |
| Midface hypoplasia           | +                 | +                 | +                 |
| Wide mouth                   | +                 | +                 | +                 |
| Long philtrum                | −                 | −                 | −                 |
| Upper lip vermilion feature  | −                 | +                 | +                 |
| Thick lower lip vermilion    | −                 | +                 | +                 |
| Palatal abnormality          | −                 | −                 | −                 |
| **Skeletal–limb**            |                   |                   |                   |
| Transverse crease            | +                 | +                 | +                 |
| Clinodactyly                 | +                 | −                 | −                 |
| Hypoplastic/absent fifth finger/toe | +           | +                 | −                 |
| Hypoplastic/absent nail (fifth finger/toe) | +   | +                 | −                 |
| Hypoplastic/absent nail (other fingers/toes) | − | +                 | −                 |
| Broad thumb                  | −                 | +                 | +                 |
| Prominent interphalangeal joints | −             | −                 | −                 |
| Prominent distal phalanges   | −                 | −                 | −                 |
| Scoliosis/spinal abnormalities | −               | +                 | −                 |
| Joint laxity                 | +                 | +                 | +                 |
| **Nervous system**           |                   |                   |                   |
| Developmental delay          | +                 | +                 | +                 |
| Seizures                     | −                 | +                 | −                 |
| Speech delay                 | +                 | +                 | +                 |
| Structural brain abnormalities | −                 | −                 | −                 |
| Agenesis of corpus callosum  | −                 | −                 | −                 |
| Hypotonia                    | +                 | +                 | +                 |
| Hypertonia                   | −                 | −                 | −                 |
| Abnormal shape of head       | +                 | +                 | +                 |
| Growth restriction           | +                 | +                 | +                 |
| Microcephaly                 | −                 | −                 | −                 |
| Others                       |                   |                   |                   |
Whole exome sequencing for the affected trios
To investigate the genetic cause of the disease, WES was performed for the trios of the two affected probands (case 2 and 3) at MyGenostics Co. LTD. Briefly, genomic DNA of each sample was quantified by NanoDrop spectrophotometry 8000 (Thermo Scientific, Waltham, MA, USA). 1 μg of genomic DNA was sheared by nebulization. Sheared DNA were ligated to the 3’ end of Illumina adapters. Products with 350–400 bp were amplified by polymerase chain reaction (PCR). The quality of the amplified products was checked using the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The amplified DNA was captured with Gencap Human whole Exon Kit (52 M) based on MyGenostics GenCap™ Enrichment Technologies (MyGenostics, Beijing, China). The capture procedure was performed according to the manufacturer’s protocol. Finally, the resultant libraries were sequenced on Illumina HiSeq 2500 platform for paired-end sequencing.

The sequencing depth was about 100× for each sample. Sequences were aligned to the human reference genome (UCSC hg19). ANNOVAR was applied to annotate the VCF file. Variants with a Minor Allele Frequency (MAF) > 0.1% or synonymous single nucleotide variants (SNVs) were removed. SNVs causing splicing, frameshift, stop gain or stop loss were kept for subsequent analysis. The location, type, conservation of the identified mutations was obtained from several public databases, such as UCSC Genome Browser, NCBI dbSNP, NCBI ClinVar, 1000 Genome and ExAC. The pathogenicity of the variants was evaluated according to the American College of Medical Genetics and Genomics (ACMG) guidelines [23] and the online software, PolyPhen-2 and SIFT for functional prediction. A position was called as heterozygous if 25% or more of the reads identify the minor allele.

Protein interaction analysis
The 12 genes for CSS and 1 for NCBRS listed in OMIM were used as input to STRING Protein–Protein interaction database (http://string-db.org/), that holds experimental, predicted and transferred interactions together with interactions obtained through text mining [24]. To select stronger interactors, network clustering was performed using k-means algorithm (number of clustering was set as 4).

Results
Clinical and demographic characteristics of three cases
Case 1 (Family 1)
The girl was G2P2, born by cesarean section at full-term of pregnancy. The birth weight was 2.95 kg. At 1 year 6 months old, the child was unable to speak, but not taken to seek medical advice. It was at the age of nearly 2 that the child could unconsciously make a “Baba-Mama” sound. At 2 years 4 months old, she was still unable to walk without support. Now, she was 3 years and 5 months old, with a weight at 11.9 kg, height 88 cm, and head circumference 48.5 cm. The pedigree and some features were depicted in Fig. 1a and b. Family history: Her parents were healthy and non-consanguineous. Her mother was 30 years old and had a healthy living style during pregnancy. The patient has a healthy 6-year-old sister.

Case 2 (Family 2)
The girl was G5P2A3, born by cesarean section at 39+3 weeks of gestation, with a birth weight of 2.65 kg,
birth height 48 cm and head circumstance 32 cm. Two months after birth, she was admitted to the Shenzhen Hospital affiliated to the University of Hong Kong for treatment due to five times of "suspicious convulsions" and diagnosed as "epilepsy". At 5 months old, her height increased to 90 cm, and weight to 11.6 kg. Her psychomotor development was significantly behind the children of the same age, and also combined with hypotonia. The pedigree and some features were depicted in Fig. 1c and d. Family history: Her healthy parents were not consanguineous. Her mother was 38 years old and had no history of smoking, drinking, long-term exposure to chemicals and harmful radiation during pregnancy. The patient has a 12-year-old brother suffered from "attention deficit hyperactivity disorder".

**Case 3 (Family 3)**
The girl was G2P2, born naturally at 39 + 1 weeks of gestation with a birth weight of 3.2 kg, height 50 cm and head circumference 34 cm. Her crying voice was weak at birth. She could not take the initiative to suck in the first two months after birth and was fed with dropper. On the 4th day after birth, she was hospitalized for 1 week due to "neonatal hyperbilirubinemia". About 1 year ago (at 8 months and 21 days old), the child could not sit alone and was treated as "developmental delay". Her cognitive and motor development was significantly lagging behind children of the same age. She could understand and execute simple instructions, and uttered no more than 5 words. At this time, her height was 94 cm, with a weight at 12.4 kg. The pedigree and some features were depicted in Fig. 1e and f. Family history: She was born of healthy, non-consanguineous parents. Her mother was 35 years old and had no history of smoking, drinking, long-term exposure to chemicals and harmful radiation during pregnancy. The patient has a healthy brother.

Clinical characters of the facial, skeletal–limb, nervous system and other features of the three cases were compiled in Table 1.

A 6q25 microdeletion was identified in case 1 by array-CGH

Oligonucleotide array-CGH was performed for the three patients using the Fetal DNA Chip (Version 1.2) designed by the Chinese University of Hong Kong (CUHK). A microdeletion at 6q25.3 was detected in case 1, arr[hg19]6q25.3(155,966,487–158,803,979) × 1. The length of this microdeletion was about 2.84 Mbp (chr6:155,966,487–158,803,979) (Fig. 2a). This deletion was not identified in her parents. Besides, there were no deletions or duplications detected in case 2 and case 3.
This deleted region contains 7 protein-encoding genes, and is highly conserved in mammals (Fig. 2b). Five of them (ARID1B, ZDHHC14, SNX9, SYNJ2 and GTF2H5) were localized on the sense strand and two (TMEM242 and SERAC1) on the antisense strand.

Two novel pathological point mutations were identified by WES

As for the other two cases, WES was performed at MyGenostics (MyGenostics, Beijing, China). The aligned bases for case 2 and case 3 were 13,859.9 and 15,678.15 Mb, respectively. The ratios of the coverage on target regions were 99.33% and 99.69%, respectively. The average sequencing depths on target regions were 109.65 and 118.64 for case 2 and case 3, respectively.

In case 2, a heterozygous SNV was detected at the splicing donor site of exon 6 (c.2332+1G > A, chr6:157,431,696) of ARID1B (NM_017519) (Fig. 3a, Table 2). It had been confirmed by Sanger sequencing (Fig. 3b). After comparing the sequences from human, chimpanzee, rhesus, cow, dog, mouse, rat and X. tropicalis, this nucleotide (2332+1G) was strongly conserved during evolution. This SNV was not detected in the several public genomic databases, such as 1000Genome Project (n=2504), NHLBI Exome Sequencing Project (GO-ESP) (n=6503), The Exome Aggregation Consortium (ExAC) (n=60,706), gnomAD (n=15,708) and NHLBI Trans-Omics for Precision Medicine (TOPMED) (n=60,000). Besides, this mutation was not identified in the parents’ genomes. Therefore, this mutation was appeared spontaneously in case 2 and should be regarded as ‘de novo’. According to criteria of ACMG guidelines, this SNV was classified as PVS1 + PS2 + PM2 and annotated as “Likely pathogenic”.

In case 3, a nonsense mutation (c.4741C > T, chr6:157,522,259) was identified in the exon 18 of ARID1B (NM_017519), causing the codon (CAG) for Gln (Q) to be a premature stop codon (TAG, X) (p.Q1581X) (Fig. 3a, d, Table 2). This mutation was verified by Sanger sequencing (Fig. 3c). This nucleotide (4492C) was strongly conserved during evolution. The mutation was not included in the large-scale genomic databases mentioned above. Since this stop gain mutation was only identified in case 3 and not in her parents, it was regarded as another ‘de novo’ variant. Besides, the variant has been annotated as rs1554235831 in NCBI dbSNP database. According to the criteria of ACMG guidelines, p.Q1581X was classified as PVS1 + PS2 + PM2 and annotated as “pathogenic”.

6q25 Microdeletions involving ARID1B

9 reported 6q25 microdeletions associated with ARID1B-related disorders were recruited from published articles. We also collected individuals with developmental disorders whose genomes containing microdeletions involving ARID1B gene from DECIPHER [25, 26] and Developmental Delay [27, 28]. 32 were from DECIPHER and 5 from Developmental Delay. The microdeletions were compared against human genome (hg19) using UCSC Genome Browser. Totally, 46 microdeletions were recruited for the subsequent analysis (Fig. 4a). 39 of them were completely (or almost) covered the whole
genomic region of ARID1B. As for the remaining partially-covered microdeletions, the shortest one (270,613, chr6:157,096,761–157,101,867) was only 5.11 Kb, just spanning the promoter region of ARID1B, just as the deletions reported by Ronzoni L in 2016 and detected in two DECIPHER samples (282,767 and 360,703). There also existed a 28.79 Kb microdeletion (274,690, chr6:157,527,273–157,556,065), which covered the whole last exon of ARID1B, thus removing part of the protein coding sequence and the complete 3'-untranslated region (3'-UTR) of ARID1B. Interestingly, the microdeletion (266,355, chr6:157,261,502–157,336,055) located in the fifth intron and did not affect the protein coding region of ARID1B. According to the chromatin modification patterns from 7 cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK and NHLF) from ENCODE (Encyclopedia of DNA Elements) [29], several candidate enhancers were located in the region covered by this deletion (266,355) (Fig. 4b).

Discussion
Currently, there are 12 genes responsible for CSSs and 1 for NCBRS, a disorder with similar phenotypes of CSSs. Among the 13 genes, except the two transcription factors, SOX4 and SOX11, proteins encoded by the remaining 11 genes were bound with each other (Fig. 5a) to form two SWI/SNF-related complex, BAF (Brg/Brahma-associated factors) complex and/or PBAF (Polybromo BRG1 Associated Factor) (Fig. 5b, c). The SWI/SNF complex was originally referred to as the protein complex critical for cellular responses to mating-type switching (SWI) or sucrose fermentation (SNF) in yeast [30, 31]. This multi-protein complex contains more than 15 subunits to activate gene expression through its capacity to remodel and remove nucleosomes at gene promoters [32]. Recently, mutations, translocations and deletions of the subunits in the SWI/SNF complex have been linked to a number of human diseases, such as cancer [33], different types of CSS [4, 34–38] and NCBRS [15].

The gene for CSS1 is ARID1B [2, 4, 39], a core subunit of the BAF complex. This gene is the most frequently mutated genes in cases with CSS [5]. The phenotypes caused by ARID1B mutations encompass a spectrum of features, including feeding difficulties, laryngomalacia, speech delay, motor delay, hypertrichosis, and cryptorchidism [40]. According to the Human Protein Atlas, ARID1B is expressed ubiquitously, and abundantly detected in never, endocrine, muscle and lymphoid systems (Fig. 5d). It is reported that meticulous coordination between the actin cytoskeleton and the microtubule...
| Cases | Sex  | Location (GRCh37/hg19) | Nucleotide   | Amino acid | Zygosity | dbSNP ID     | Origin     | ACMG       | Population frequences | Impact              |
|-------|------|------------------------|--------------|------------|----------|--------------|------------|------------|-----------------------|---------------------|
| 2     | Female | chr6:157,431,696     | c.2332+1G>A | –          | Het      | –            | De novo    | PVS1 + PS2 + PM2 | –                     | Splicing donor loss |
| 3     | Female | chr6:157,522,259     | c.4741C>T   | p.Q1581X   | Het      | rs1554235831 | De novo    | PVS1 + PS2 + PM2 | –                     | Stop gain            |

Het, heterozygous; X, stop codon; PVS1, pathogenic very strong, represent "loss-of-function"; PS2, pathogenic strong, 2 represent "de novo"; PM2, pathogenic moderate, 2 represent "absent from controls"
Fig. 4 Mapping of microdeletions involving ARID1B. 

a. Mapping of the microdeletions involving ARID1B. 

b. Zoomed-in view of the microdeletions. 

Red bar represents microdeletions.
network regulate the formation and transportation of secretory vesicles for proper neurite outgrowth and maintenance, which is critical for normal neural development [41]. This finely-tuned coordination is regulated by the BAF complex [42]. ARID1B (previously named as BAF250B) is a core member of the BAF complex and plays an essential role for dendrite outgrowth and arborization in cortical and hippocampal pyramidal neurons during brain development in mice [43]. ARID1B deficiency led to decreased dendritic branching, thus hinder the dendritic innervation into cortical layer I to form proper synapses. This might disrupt the balanced excitatory and inhibitory inputs and result in pathologic phenotypes of ID.

**ARID1B is the crucial pathogenic factor behind 6q25 microdeletion-related disorder**

In our case 1, there exists a heterozygous microdeletion arr[hg19]6q25.3(155,966,487–158,803,979) × 1 (Fig. 3a). This region contains 7 protein-coding genes, namely, ARID1B, TMEM242, ZDHHC14, SNX9, SYNJ2, SERAC1 and GTF2H5. It is worth noting that several inheritable disease-causing genes were recruited in the OMIM database. **ARID1B** (OMIM#614556) is the causal gene for CSS1 (OMIM#135900). **GTF2H5** (general transcription factor IIF subunit 5, OMIM#608780) could result in the photosensitive trichothiodystrophy-3 (TTD3) (OMIM#616395) [44–46], a rare autosomal recessive disorder characterized by brittle sulfur-deficient hair, ichthyosis, developmental disabilities, decreased fertility, ocular abnormalities, short stature, and infections [47]. **SERAC1** (serine active site containing 1, OMIM#614725) functions in phosphatidylglycerol remodeling that is essential for mitochondrial function and intracellular cholesterol trafficking [48]. Bi-allelic Mutations of this gene were associated with 3-methyl-glutaric aciduria, accompanied with deafness, encephalopathy and Leigh-like syndrome (MEGDHEL, OMIM#614739) [48–50]. **TMEM242** was reported to affect the assembly of the ATP synthase and mitochondrial complex I, to a certain degree [51]. **ZDHHC14** (zinc finger DHHC-type palmitoyl transferase 14) is highly expressed in the hippocampus and is the only palmitoyl acyltransferase (PAT) predicted to bind Type-I PDZ domain-containing Membrane-associated Guanylate Kinase PSD93, which localizes to the axon initial segment (AIS) [52]. Loss of **ZDHHC14** decreases

---

**Fig. 5** Interaction of proteins for CSS and structures of SWI/SNF-related proteins. **a** Interactions of the 12 proteins for Coffin–Siris syndrome and 1 for NCBRS. **b** Structures of BAF. **c** Structures of PBAF. **d** Expression of ARID1B in different tissues of human (adopted from the Human Protein Atlas).
outward currents and increases action potential firing in hippocampal neurons. SNX9 (Sorting nexin 9), a member of the sorting nexin family, is required for membrane remodeling during endocytosis [53]. As for SYNJ2 (synaptojanin 2), it is a ubiquitously expressed phosphoinositol 5-phosphatase, involved in vesicular trafficking and actin dynamics. Although it is not clear whether SYNJ2 played a role in the normal brain development, an association study showed that SYNJ2 was associated with general memory and general cognitive ability [54].

Based on the above analysis, ARID1B, GTF2H5, SERAC1 and ZDHHC14 might be the promising candidates responsible for the 6q25 microdeletion syndrome. Currently, there are more than 10 reported individuals harboring 6q25 microdeletions [2, 55–59]. The reported shortest 6q25 deletion (1.1 Mb, chr6:156,004,307–157,120,089) contained only one protein-coding gene, ARID1B [60]. According to the ARID1B-related deletions collected in DECIPHER and Developmental Delay, the shortest deletion (270,613) was only 5.11 Kb, just spanning the promoter region and first exon of ARID1B. This deletion made ARID1B unable to start the transcription, just as the deletions reported by Ronzoni L in 2016 and detected in two DECIPHER samples (282,767 and 360,703). There also existed a 28.79 Kb microdeletion (274,690), which covered the whole last exon of ARID1B, thus removing part of the protein-coding sequence and the complete 3′-UTR of ARID1B. The transcription of ARID1B could not stop at the normal termination site, and might produce truncated proteins without the C-terminal BAF250_C domain (pfam12031). Interestingly, the microdeletion (266,355) just located in the middle of ARID1B, just like the sample 389,566. According to the chromatin modification patterns from 7 cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK and NHLF) from ENCODE, several candidate enhancers were located in this region (Fig. 5b). Loss of these enhancers might affect the transcription efficiency of ARID1B. Therefore, the insufficient production of ARID1B could be caused by four types of 6q25 microdeletions, namely whole genomic region, promoter region, termination region and enhancer regions.

Haploinsufficiency of ARID1B has been reported to be recurrently detected in intellectual disability (ID) or mental retardation (MRT) [60, 61], therefore, ARID1B might be the crucial pathogenic factor behind the 6q25 microdeletion syndrome.

Haploinsufficiency of ARID1B caused by de novo SNVs

In case 2, a variant at the splicing site of exon 6 (c.2332+1G>A) of ARID1B (NM_017519) was identified. This variant disrupted the splicing donor site (GT) of intron 6, which might affect the proper splicing of ARID1B’s mRNA during transcription to produce abnormal transcripts, thus to inactivate the function of ARID1B. It is reported that heterozygous mutations of splicing sites could affect splicing and lead to haploinsufficiency of the affected genes [62, 63]. Therefore, it is reasonable that c.2332+1G>A mutation might be detrimental the proper splicing and result to insufficient expression of ARID1B.

In case 3, the mutation (c.4741C>T) was located in exon 18 of ARID1B, causing the codon (CAG) for Q to be a premature termination codon (TAG) (p.Q1581X). The transcript contains two stop codons (one at position 1581 and another at position 2237). It had been reported that mRNAs containing premature termination codons (PTC) could be detected and degrade rapidly by a special mRNA surveillance mechanism, Nonsense-mediated mRNA decay (NMD). It is widely accepted that the biological purpose of NMD is to protect cells from potential harmful effects caused by truncated translational products as a consequence of frameshift or nonsense mutations or by inaccurate pre-mRNA splicing [64–66]. It is been found that in 143 patients with CSS, all pathogenic variants were truncating (nonsense, frameshift, splice-site, and deletions of various numbers of exons including whole-gene deletions). Therefore, these two de novo single nucleotide variants in our project might lead to haploinsufficiency of ARID1B and be pathogenic for CSS.

Treatments for ARID1B-related disorders

Till now, there has no effective treatments for ARID1B-related disorders. The present methods are symptomatic treatment and cannot cure this disease. Currently, a clinical trial is ongoing to investigate the effects of clonazepam on children with ARID1B-related intellectual disability in Netherlands (EudraCT: 2019-003558-98). The purpose of this clinical trial is to test the beneficial effects of clonazepam on behavior and cognitive function in ARID1B patients.

Animal with ARID1B haploinsufficiency (Arid1b+/−) would be promising models for the study of molecular mechanism and discovering of drugs for ARID1B-related disorder. The Arid1b+/− C57BL/6J mice showed reduced corpus callosum size, dentate gyrus size, cortex thickness, and proliferation [67–69]. It was found that deficiency of GHRH–GH–IGF1 axis was detected in Arid1b+/− mice [67]. Exogenous GH supplementation could significantly reverse the growth retardation in Arid1b+/− mice, but no improvement on abnormal behavioral phenotypes such as anxiety. This indicated there might be other critical unknown druggable targets for the treatment of ARID1B-related disorder. Or Arid1b+/− mice might not be the most suitable animal for the study of ARID1B-related disorder.
Conclusions
Here we identified a patient with haploinsufficiency of ARID1B caused by a 2.84 mb 6q25 microdeletion and two caused by loss-of-function (LoF) mutations of ARID1B. All of the three abnormalities were acquired spontaneously. ARID1B gene was the critical genetic factor for ARID1B-related disorder. Besides, four types of 6q25 microdeletion were identified by silico analysis. This would broaden the knowledge about ARID1B mutation spectrum for clinicians and genetic counselor.

Abbreviations
CSS: Coffin–Siris syndrome; LoF: Loss-of-function; NCBRS: Nicolaides–Baraitser syndrome; SWI/SNF: Mating-type switching (SWI) or sucrose fermentation (SNF); ARID1B: AT-rich interaction domain 1B; Array-CGH: Array-comparative genomic hybridization; CUHK: Chinese University of Hong Kong; MAF: Minor allele frequency; OMIM: Online Mendelian inheritance in man; WES: Whole-exome sequencing; SNVs: Single nucleotide variants; ExAC: The exome aggregation consortium; ESP: NHLBI exome sequencing project; GTF2HS: General transcription factor IIH subunit 5; TTDS: Trichothiodystrophy-3; SERAC1: Serine active site containing 1; MEGDHEL: 3-Methyl-glutaric aciduria, accompanied with deafness, encephalopathy and Leigh-like syndrome; ZDHHC14: Zinc finger DHHC-type palmitoyl transferase 14; PAT: Palmitoyl acyltransferase, AIS: Axon initial segment; SNX9: Sorting nexin 9; SYNJ2: Synaptojanin 2; ID: Intellectual disability; MRT: Mental retardation; PTC: Premature termination codons; NMD: Nonsense-mediated mRNA decay.

Acknowledgements
The authors thank the families and referring physicians for participation in these studies. The authors also thank MyGenostics for WES and analyzing the exome sequencing data.

Authors’ contributions
GL conceived the project, analyzed the data and wrote the manuscript. JZ and LW collected samples and extracted genomic DNAs. LM conceived the project, revised the manuscript and supervised the project and revised the manuscript. QP performed genetic counseling, analyzed the clinical data and revised the manuscript. GL and QP contributed equally to this work. All authors read and approved the final manuscript.

Funding
This work was supported by Grants from the Science and Technology Research and Development Foundation of Shenzhen City (JCYJ20180305164359668 to PQ and JCYJ20190809183601667 to ML), Key Research and Development Project of Deyang City’s Science and Technology Bureau (21DZYF0011 to GL.), Special Fund for Incubation Projects of Deyang People’s Hospital (FHG202004 to GL.). The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets about whole exome sequencing used for the current study were available at https://www.ncbi.nlm.nih.gov/sra/?term=PRUNA777349.

Declarations
Ethics approval and consent to participate
This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. This study was approved by the Ethical Committee of the Shenzhen Baan Women’s and Children’s Hospital. We obtained written informed consent from all individual members included in the study. As for the minors, written informed consent was obtained from the parents or legal guardians.

Consent for publication
Written informed consent was obtained from the patients for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. As for the minors, written informed consent was obtained from the parents or legal guardians.

Competing interests
The authors declare that they have no competing interests.

Received: 2 August 2021 Accepted: 5 November 2021
Published online: 14 November 2021

References
1. Vergano SS, Deardorff MA. Clinical features, diagnostic criteria, and management of Coffin–Sirs syndrome. Am J Med Genet Part C Semin Med Genet. 2014;166C(3):252–6.
2. Hoyer J, Ekiab AC, Endele S, Popp B, Zweier C, Wiesener A, Wohlebber E, Dufke A, Rossier E, Petch C, et al. Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet. 2012;90(3):565–72.
3. Santen GW, Aten E, Volto-van Silhout AT, Pottinger C, van Bon BW, van Minderhout JJ, Snoedeveld R, van der Lans CA, Boogaard M, Linseisen MM, et al. Coffin–Sirs syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat. 2013;34(11):1519–28.
4. Tsurusaki Y, Okamoto N, Ohashi H, Koshio T, Imai Y, Hibi-Ko Y, Kaname T, Nanotomi K, Kawame H, Waku K, et al. Mutations affecting components of the SWI/SNF complex cause Coffin–Sirs syndrome. Nat Genet. 2012;44(4):378–8.
5. Wieczorek D, Bogershausen N, Beleigglia F, Steiner-Haldenstein S, Pohl E, Li Y, Milz E, Martin M, Theile H, Altmuller J, et al. A comprehensive molecular study on Coffin–Sirs and Nicolaides–Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling. Hum Mol Genet. 2013;22(25):5121–35.
6. Shang L, Cho MT, Retterer K, Folk L, Humberson J, Rhoena L, Sidhu A, Saliganan S, Iglesia A, Wizaka P, et al. Mutations in ARID2 are associated with intellectual disabilities. Neurogenetics. 2015;16(4):307–14.
7. Vasileiou G, Vergarajuregui S, Endele S, Popp B, Butterm C, Ekiab AC, Gerard M, Bramswig NC, Albrecht B, Clayton-Smith J, et al. Mutations in the BAF-complex subunit DP2 Are associated with Coffin–Sirs syndrome. Am J Hum Genet. 2018;102(3):468–79.
8. Machol K, Rousseau I, Ehrensmiss S, Garcia T, Nguyen TTM, Spellmann RC, Sullivan JA, Shashi V, Jiang YH, Ston L, et al. Expanding the spectrum of BAF-related disorders: de novo variants in SMARCC2 cause a syndrome with intellectual disability and developmental delay. Am J Hum Genet. 2019;104(1):164–78.
9. Tsurusaki Y, Kohsimitu E, Ohashi H, Pakdeke S, Iou J, Shima M, Suzuki T, Okamoto N, Inamaru S, Yamashita M, et al. De novo SOX11 mutations cause Coffin–Sirs syndrome. Nat Commun. 2011;3:4011.
10. Zawerton A, Yao B, Yeager JP, Pippucci T, Haseeb A, Smith JD, Wischmann L, Kuhl SJ, Dean JCS, Pilz DT, et al. De novo SOX4 variants cause a neurol developmental disease associated with mild dysmorphism. Am J Hum Genet. 2019;104(2):246–59.
11. Nixon NC, Rousseau J, Stone MH, Sarikahya M, Ehrensmiss S, Mizuno S, Matsumoto N, Miyake N, Study DDD, Baralle D, et al. A syndrome neu rol-developmental disorder caused by mutations in SMARCD1, a core SWI/SNF subunit needed for context-dependent neuronal gene regulation in flies. Am J Hum Genet. 2019;104(4):596–610.
12. Barish S, Barakat TS, Michel BC, Nashlair N, Phillips JB, Valencia AM, Ugur B, Wegner J, Scott TM, Bostwick B, et al. BICRA, a SWI/SNF complex component of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Brain Dev. 2015;37(5):527–36.
13. Wolff D, Endele S, Azzarello-Burri S, Hoyer J, Zweier M, Carigiani G, B, Rauch A, Reis A, Zeeher C, In-frame deletion and missense mutations of the C-terminal helicase domain of SMARCA2 in three patients with Nicolaides–Baraitser syndrome. Mol Syndromol. 2012;2(6):237–44.
34. Vasko A, Drivas TG, Schrier Vergano SA. Genotype-phenotype correlations in 208 individuals with Coffin–Siris syndrome. Genes. 2021;12(6):937.

35. Mashtalir N, D’Avino AR, Michel BC, Luo J, Pan J, Otto JE, Zullo HV, McKenzie ZM, Kubiai RL, St Pierre R, et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell. 2018;175(5):1272–88.

36. Man L, Gourhan RPA, Mohan SS. SWI/SNF infobase-an exclusive information portal for SWI/SNF remodeling complex subunits. PLoS ONE. 2017;12(9):e0184445.

37. Schick S, Rendeiro AF, Runggatscher K, Ringler A, Boidol B, Hinkel M, Majek P, Vuillard L, Penz T, Parapatics K, et al. Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers. Nat Genet. 2019;51(5):1399–410.

38. Srikant S, Ramachandran S, Mohan SS. Construction of the gene regulatory network identifies MYC as a transcriptional regulator of SWI/SNF complex. Sci Rep. 2020;10(1):158.

39. Zweier M, Peippo MM, Poyhonen M, Kaarianen H, Begemann A, Jost B, Omeda B, Rauch A. The HHID syndrome of hypertrichosis, hyperkeratosis, abnormal corpus callosum, intellectual disability, and minor anomalies is caused by mutations in ARID1B. Am J Med Genet Part A. 2017;173(5):1440–3.

40. van der Sluis PJ, Jensen S, Vergano SA, Janssen EM, Alanay Y, AlKindy A, Baban A, Bayat A, Beck-Wind W, Berry K, et al. The ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin–Siris syndrome. Genet Med. 2019;21(6):1295–307.

41. Tkaczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucl Acids Res. 2021;49(D1):D605–12.

42. Neigeborn L, Carlson M. Genes affecting the regulation of SUC2 gene expression in Saccharomyces cerevisiae. Genetics. 2000;154(2):915–23.

43. Ka M, Chopra DA, Dravid SM, Kim YW. Essential roles for ARID1B in dendiric arborization and spine morphology of developing pyramidal neurons. J Neurosci. 2016;36(9):840–57.

44. Michaliska E, Koppolu A, Dobrzaniska A, Ploski R, Gruszfeld D. A case of severe trichothiodystrophy 3 in a neonate due to mutation in the GTF2HS gene: clinical report. Eur J Med Genet. 2019;62(6):103567.

45. Moriwaki S, Saruwatari H, Kanzaki T, Kanekura T, Minoshima S. Trichothiodystrophy group A: a first Japanese patient with a novel homozygous nonsense mutation in the GTF2HS gene. J Dermatol. 2014;41(8):705–8.

46. Giglia-Mari G, Ciof F, Ranish JA, Hooogrdenstraat D, Theil A, Wijgers N, Theil A, Wijgers N, Jaspers NG, Raams A, Argentini M, van der Spek P, et al. A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A. Nat Genet. 2004;36(7):714–9.

47. Faghi S, Tamura D, Kraemer KH, Diogiovanna JJ. Trichothiodystrophy: a systematic review of 112 published cases characterises a wide spectrum of clinical manifestations. J Med Genet. 2006;43(10):609–21.

48. Wortmann SB, Vaz FM, Gardetchik T, Vissers LE, Renkema GH, Schuurs-Hoejemakers JH, Kulk W, Lammers M, Christin C, Kluftman LA, et al. Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet. 2012;44(7):789–92.

49. Tort F, Garcia-Silva MT, Ferrer-Cortes X, Navarro-Sastre A, Garcia-Villoria J, Coll MJ, Vidal E, Jimenez-Almazan J, Dapozo J, Priones P, et al. Exome sequencing identifies a new mutation in SERAC1 in a patient with 3-methylglutaconic aciduria. Mol Genet Metab. 2013;109(4):314–9.

50. AlKindy A, Baban A, Bayat A, Beck-Wind W, Berry K, et al. The ARID1B mutation panel in the diagnosis of Charcot-Marie-Tooth disease. Neurology. 2017;88(1):158.

51. Mani U, Goutham RNA, Mohan SS. SWI/SNF infobase-an exclusive information portal for SWI/SNF complex. Sci Rep. 2020;10(1):158.

52. Sanders SS, Hernandez LM, Soh H, Karnam S, Wolkonis RS, Tzingounis AV, Thomas GM. The palmitoyl acyltransferase ZDHHC14 controls Kv1 family potassium channel clustering at the axon initial segment. Elife. 2020;9:e56056.
54. Lopez LM, Harris SE, Luciano M, Liewald D, Davies G, Gow AJ, Tenesa A, Payton A, Ke X, Whalley LJ, et al. Evolutionary conserved longevity genes and human cognitive abilities in elderly cohorts. Eur J Hum Genet. 2012;20(3):341–7.

55. Nagamani SC, Erez A, Eng C, Ou Z, Chaintault C, Workman L, Coldwell J, Stankiewicz P, Patel A, Lupski JR, et al. Interstitial deletion of 6q25.2-q25.3: a novel microdeletion syndrome associated with microcephaly, developmental delay, dysmorphic features and hearing loss. Eur J Hum Genet. 2009;17(5):573–81.

56. Paulraj P, Palumbo JC, Openshaw A, Carey JC, Toydemir RM. Multiple congenital anomalies and global developmental delay in a patient with interstitial 6q25.2q26 deletion: a diagnostic odyssey. Cytogenet Genome Res. 2018;156(4):191–6.

57. Michelson M, Ben-Sasson A, Vinkler C, Leshinsky-Silver E, Netzer I, Frumkin A, Kivity S, Lerman-Sagie T, Lev D. Delineation of the interstitial 6q25 microdeletion syndrome: refinement of the critical causative region. Am J Med Genet Part A. 2012;158A(6):1395–9.

58. Pirola B, Borzotto L, Giglio S, Piovan E, Janes A, Guerrini R, Zuffardi O. Agenesis of the corpus callosum with Probst bundles owing to haploinsufficiency for a gene in an 8 cM region of 6q25. J Med Genet. 1998;35(12):1031–3.

59. Shen-Schwarz S, Hill LM, Surti U, Marchese S. Deletion of terminal portion of 6q: report of a case with unusual malformations. Am J Med Genet. 1989;32(1):81–6.

60. Ronzoni L, Tagliabueri F, Tucci A, Baccarin M, Esposito S, Milani D. Interstitial 6q25 microdeletion syndrome: ARID1B is the key gene. Am J Med Genet Part A. 2016;170A(5):1257–61.

61. Peter B, Lancaster H, Vose C, Fares A, Schrauwen I, Huettelman M. Two unrelated children with overlapping 6q25.3 deletions, motor speech disorders, and language delays. Am J Med Genet Part A. 2017;173(10):2659–69.

62. De Crescenzo A, Citro V, Freschi A, Sparago A, Palumbo O, Cubellis MV, Carella M, Castelluccio P, Cavaliere ML, Cerrato F, et al. A splicing mutation of the HMGA2 gene is associated with Silver-Russell syndrome phenotype. J Hum Genet. 2015;60(6):287–93.

63. Fischer-Zimsak B, Segebrecht L, Schubach M, Charles P, Alderman E, Brown K, Cadieux-Dion M, Cartwright T, Chen Y, Costin C, et al. Haploinsufficiency of the notch ligand DLL1 causes variable neurodevelopmental disorders. Am J Hum Genet. 2019;105(3):631–9.

64. Kamelgarn M, Chen J, Kwang L, Jin H, Kasarskis EJ, Zhu H. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. Proc Natl Acad Sci USA. 2018;115(51):E1904–13.

65. Yan Q, Weyn-Vanheentenryck SM, Wu J, Sloan SA, Zhang Y, Chen K, Wu JQ, Barnes BA, Zhang C. Systematic discovery of regulated and conserved alternative exons in the mammalian brain reveals NMD modulating chromatin regulators. Proc Natl Acad Sci USA. 2015;112(11):3445–50.

66. Shyu AB, Wilkinson MF, van Hoof A. Messenger RNA regulation: to translate or to degrade. EMBO J. 2008;27(3):471–81.

67. Celen C, Chuang JC, Luo X, Nijem N, Walker AK, Chen F, Zhang S, Chung AS, Nguyen LH, Nassour I, et al. Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment. Elife. 2017;6:e25730.

68. Shibutani M, Hori T, Shoji H, Morita S, Kimura M, Terawaki N, Miyakawa T, Hatada I. Arid1b haploinsufficiency causes abnormal brain gene expression and autism-related behaviors in mice. Int J Mol Sci. 2017;18(9):1872.

69. Ellegood J, Petkova SP, Kimman A, Qiu LR, Adhikari A, Wade AA, Fernandez D, Lindenmaier Z, Creighton A, Nutter LM, et al. Neuroanatomy and behavior in mice with a haploinsufficiency of AT-rich interactive domain 1B (ARID1B) throughout development. Mol Autism. 2021;12(1):25.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.